Abstract
In findings that conflict with those of other recent studies, a new 12‐month trial has found that long‐acting injectable risperidone was more effective than the oral formulation of the antipsychotic in controlling psychotic symptoms and preventing relapse in patients with recent onset of schizophrenia. The trial differed from other studies in that all patients in the comparison group received oral risperidone, rather than any one of a variety of oral antipsychotics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
